Elahere

mirvetuximab soravtansine-gynx

Approval

ApplicationBLA 761310
Approval dateNov 14, 2022
Approval year2022
SponsorImmunogen INC

FDA-approved use

To treat patients with recurrent ovarian cancer that is resistant to platinum therapy

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Elahere: